InvestorsHub Logo
Followers 275
Posts 32725
Boards Moderated 0
Alias Born 11/14/2013

Re: iwasadiver post# 239917

Thursday, 08/15/2019 9:31:04 PM

Thursday, August 15, 2019 9:31:04 PM

Post# of 703334
Good point, and the study uses minimum follow up of four years.

Trials of nivolumab in the second-line or later setting with at least 4 years follow-up were included.



(Small correction, BMY makes Nivolumab, not Keytruda.)

Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News